Podcasts about Progression

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3050: Sam Lynch highlights the vital distinction between training and working out, showing how a structured approach can turn effort into measurable progress. While working out keeps you moving, training ensures each session builds toward your specific goals with intention, progression, and accountability. Read along with the original article(s) here: https://fitnitiative.co.uk/2021/09/22/training-vs-working-out/ Quotes to ponder: "A workout is singular and doesn't take into consideration the scope of the next, or the previous workout." "Training gives direction to your workouts, making each individual session, and component of those sessions, compliment the others in the program." "You may well get there, but you won't know how. Or worse, you may not get to point B and be unable to identify where you went wrong." Episode references: Physical Activity Guidelines for Americans: https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf Learn more about your ad choices. Visit megaphone.fm/adchoices

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3050: Sam Lynch highlights the vital distinction between training and working out, showing how a structured approach can turn effort into measurable progress. While working out keeps you moving, training ensures each session builds toward your specific goals with intention, progression, and accountability. Read along with the original article(s) here: https://fitnitiative.co.uk/2021/09/22/training-vs-working-out/ Quotes to ponder: "A workout is singular and doesn't take into consideration the scope of the next, or the previous workout." "Training gives direction to your workouts, making each individual session, and component of those sessions, compliment the others in the program." "You may well get there, but you won't know how. Or worse, you may not get to point B and be unable to identify where you went wrong." Episode references: Physical Activity Guidelines for Americans: https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf Learn more about your ad choices. Visit megaphone.fm/adchoices

Jakub Remiar dives into Uma Musume Pretty Derby's “Spark” and legacy mechanics—one of the most advanced progression and inheritance systems in any mobile RPG. See why this game's depth is pulling 100,000 downloads a day and racking up 450,000 dollars daily revenue even outside Japan. From Genshin-style stat RNG to community-driven parent borrowing, you'll learn why this system is built for both theorycrafters and casuals, and why it's suddenly trending in the West.You'll learn:How legacy and spark inheritance work, and why this is deeper than anything in Western gachaWhy are there sixty-page guides and two hundred-page translations just to optimize your teamThe power of borrowing “whale” parents and building the perfect runHow no-level, stat-based progression makes Uma Musume endlessly replayableWhat makes this system so viral on YouTube, Shorts, and Steam right nowWhy every risk-reward decision and endless RNG roll keeps the meta aliveGet our MERCH NOW: 25gamers.com/shop--------------------------------------PVX Partners offers non-dilutive funding for game developers.Go to: https://pvxpartners.com/They can help you access the most effective form of growth capital once you have the metrics to back it.- Scale fast- Keep your shares- Drawdown only as needed- Have PvX take downside risk alongside you+ Work with a team entirely made up of ex-gaming operators and investors---------------------------------------Vibe. Vibe is the leading Streaming TV ad platform for small and medium-sized businesses looking for actionable advertising campaign performance.https://www.vibe.co/---------------------------------------For an ever-growing number of game developers, this means that now is the perfect time to invest in monetizing direct-to-consumer at scale.Our sponsor FastSpring:Has delivered D2C at scale for over 20 yearsThey power top mobile publishers around the worldLaunch a new webstore, replace an existing D2C vendor, or add a redundant D2C vendor at fastspring.gg.---------------------------------------This is no BS gaming podcast 2.5 gamers session. Sharing actionable insights, dropping knowledge from our day-to-day User Acquisition, Game Design, and Ad monetization jobs. We are definitely not discussing the latest industry news, but having so much fun! Let's not forget this is a 4 a.m. conference discussion vibe, so let's not take it too seriously.Panelists: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jakub Remia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠r,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Felix Braberg, Matej Lancaric⁠Youtube: https://youtu.be/jk7CmPs4JRYJoin our slack channel here: https://join.slack.com/t/two-and-half-gamers/shared_invite/zt-2um8eguhf-c~H9idcxM271mnPzdWbipgChapters00:00 Introduction to Umo Musume Pretty Derby04:54 The Roguelite System Explained08:12 The Legacy System and Its Importance11:05 Understanding the Spark System13:59 Social Mechanics and Community Impact16:53 Replayability and Randomness in Gameplay20:13 Future Potential and Game Design Insights---------------------------------------Matej LancaricUser Acquisition & Creatives Consultant⁠https://lancaric.meFelix BrabergAd monetization consultant⁠https://www.felixbraberg.comJakub RemiarGame design consultant⁠https://www.linkedin.com/in/jakubremiar---------------------------------------Please share the podcast with your industry friends, dogs & cats. Especially cats! They love it!Hit the Subscribe button on YouTube, Spotify, and Apple!Please share feedback and comments - matej@lancaric.me---------------------------------------If you are interested in getting UA tips every week on Monday, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠lancaric.substack.com⁠⁠⁠⁠⁠⁠ & sign up for the Brutally Honest newsletter by Matej LancaricDo you have UA questions nobody can answer? Ask ⁠⁠⁠⁠⁠⁠⁠⁠Matej AI⁠⁠⁠⁠⁠⁠ - the First UA AI in the gaming industry! https://lancaric.me/matej-ai

Ken Murray and I talk about one of the wonders of coming events:  What will happen to human civilization?  When and how will it end?  There is a straightforward biblical summary of what will happen.   The end of civilization will not come tomorrow.  There is still a lot that has to happen. An outline of the future will anchor us in being productive and useful now.  At the same time, we pray for God's Kingdom....His new remake of civilization to come.   See the reference handout for this podcast here.   

01 Agustin Gatti - Nightwolf 02 NAV (RU) - Levitation 03 Dylhen - Roaches (Cendryma Remix) 04 Dylhen - Roaches (Tiefstone Remix) 05 Rodrigo Pochelu & Diego Acosta (UY) - Black Cat 06 Nikhila Hashen - Small Wins (Dr Green Remix) 07 Tato Seco - Boba Fett 08 AZLN - Purple Honey 09 MOB (LB) - Vibrance (Sam Scheme Remix) 10 Emcroy - Organic Space (Ignacio Hernández Remix) 11 Agustin Pietrocola - Voices of Sea 12 Cesar Herresuelo - The Side 13 Alexis Ludd - The Return 14 Tato Seco - Jikai Made (HAFT Remix) 15 Indigo Man - Similarity (Mayro Remix) 16 DEGG (MT) - Radiant Life (Randle Remix) 17 GMJ & Matter - Apex 18 Nicky (SL) - Ethnical Impact 19 DERK & DEMIS (AR) - EANP Tunna (Remix) 20 Glenn Molloy - Bittersweet 21 Quivver - Hype 25 22 George X - Sunday's Memory 23 Cengiz Guzel & Teleport-X - Never Let You Go 24 Martin Di Sciascio - Purple Dreams 25 Chris Drifter - Suburban Wolf (Lightning Effect Remix) 26 Paul Oakenfold - Novacaine (Paul Oakenfold Dark Extended Mix) 27 Deep Lo - Progressive Stream 28 Nico Martinez - Lucius Noise

Trotz Widerstand aus der Bevölkerung, will die Zürcher Regierung ihre Plän durchziehen und die Glattalbahn ausbauen. Eine Lösung, die der Kanton vorschlägt, ist die Verlängerung der Bahn bis nach Kloten. Weitere Themen: · Windmessmasten in Wiesendangen und Rickenbach stossen auf Widerstand. · Zürcher Regierungsrat will gegen Kürzungen bei Jugend+Sport kämpfen. · Kanton Zürich gleicht kalte Progression aus. · Stadt Zürich pflanzt mehr Bäume in Altstetten. · Die Stadt Zürich versinkt bei Fussball-Spielen währen der Euro 25 in Feierlaune: unsere Reportage. · Stricken im Kinosaal - dieser neue Trend stösst auf Anklang: unsere Reportage aus einem Zürcher Kino.

In today's episode we are discussing 2 journal club articles relating to risk factors of glaucoma with our Mayo Clinic colleague Dr Arthur Sit.   Long-Term Systemic Use of Calcium Channel Blockers and Incidence of Primary Open-Angle Glaucoma - Ophthalmology Glaucoma Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study - PubMed Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com Follow and reach out to us on X and IG: @mayocliniceye

Bible Study | Pastor M. L. Whitlock

In this powerful episode of Shadow Work, WTF?, Caitlin sits down with SJ Chiovitti to unpack one of the most uncomfortable yet crucial conversations in the coaching industry: coercive control. With the recent introduction of coercive control laws in Australia, this conversation explores how these dynamics extend far beyond intimate relationships into coaching spaces, creating environments where clients slowly lose their autonomy and self-trust. SJ brings her background in psychology, behavioural finance, and trauma counselling to break down how seemingly supportive mentorship can become psychological captivity—and what we can all do differently.This episode is for you if:You've ever felt like you couldn't disagree with or question your coach without consequencesYou're a coach wondering if you're unconsciously creating codependent dynamics with clientsYou've noticed yourself adopting your mentor's language, style, or opinions without conscious choiceYou want to understand the difference between ethical influence and manipulation in coachingWhat we'll cover:How coercive control manifests in coaching spaces through subtle emotional manipulation and power imbalancesThe predictable progression from admiration to psychological dependence in mentoring relationshipsWhy spiritual and personal development language can be weaponised to avoid accountabilityPractical steps for coaches to create genuinely empowering, sovereignty-supporting containersKey Points and Timestamps:01:42:00 - Defining Coercive ControlSJ breaks down what coercive control actually means and how it removes true consent through psychological pressure disguised as care.09:42:00 - The Progression into High ControlHow coaching relationships start with admiration and gradually shift into psychological captivity through pedestalling and power imbalances.22:50:00 - Creating Ethical Coaching SpacesPractical guidance for coaches on how to maintain client sovereignty, ask before offering insight, and make repair normal rather than rare.43:15:00 - Building Capacity to Speak TruthSJ shares her journey of developing the nervous system capacity to call out harmful patterns while modelling better alternatives.1:04:04:00 - Red Flags and Next StepsClear warning signs to watch for and actionable steps for both coaches and clients to create or find healthier dynamics.Resources Mentioned:Follow SJ Chiovitti: @sj.chiovittiShadow Alchemy Certification: shadowalchemycoaching.comShadow Alchemy Coaching Academy: @shadowalchemycoachingacademyConnect with Us:This conversation challenges some deeply embedded norms in the coaching industry. Share your thoughts with us @shadowalchemycoachingacademy⁠.If you're ready to learn how to create genuinely ethical coaching containers that support client sovereignty rather than dependence, Shadow Alchemy Certification teaches shadow work through embodied practice and ethical frameworks. Our next immersion is coming up, and we're committed to raising the standard of safety in this industry. Learn more at shadowalchemycoaching.com.

Avant tout, laisse moi te parlerdes Rencontres de la Performance. C'est LE rendez-vous de l'année. le 14-15-16 novembre à Paris. Au programme : des conférences, des ateliers, des échanges avec un seul objectif, que tu repartes avec du concret à mettre sur le terrain ! Pour plus d'informations : https://www.secretsdentraineurs.com/event/rencontres-de-la-performance-4/register Utilise le code SECRETS pour bénéficier de -10% sur ta place ! __________ Romain est le préparateur physique du FC Grenoble Rugby. On se connait depuis des années et j'adore sa philosophie d'entrainement. Il a démocratisé les entrainements "anti déformation" Dans cet épisode tu trouveras : Entrainer le gainage Les facteurs de performance au rugby L'aspect holistique de la performance Individualiser au sein d'une équipe Coacher et communiquer__________ Je tiens à remercier Laroq pour leur soutien sans faille depuis plus d'un an. Ils créent du matériel 100% français d'excellente qualité et surtout financièrement abordable : moins cher que leurs concurrents qui produisent en Chine ! Si ça t'intéresse, rdv : www.laroq.fr __________ Retrouve nous sur les réseaux sociaux : Instagram : https://www.instagram.com/secretsdentraineurs/ Linkedin : https://www.linkedin.com/in/julien-vecchione-714147155/Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Mobilisation de près de 1000 pompiers pour lutter contre les violents incendies qui ravagent le sud de la France, notamment dans les régions de Marseille, l'Hérault et l'Aude.Progression fulgurante des flammes, attisées par de fortes rafales de vent, ayant déjà parcouru plus de 700 hectares.Évacuations préventives de centaines d'habitants dans certains secteurs menacés.Inquiétudes des autorités face à la sécheresse et aux conditions météorologiques propices aux départs de feux.Incident évité de justesse lors de la 4e étape du Tour de France à Rouen, où un individu armé d'un couteau a été maîtrisé par les forces de l'ordre.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Career Sponsorship has become critical to women's advancement to leadership. Today, we are discussing the behaviours and actions the most exceptional Sponsors are taking to ensure more talented women are promoted to leadership.Systemic bias means that men are exposed to opportunities in their careers more readily than their female peers are. Career Sponsors are needed to address that imbalance. Sponsors are influential leaders within an organisation, who believe in the moral and commercial importance of inclusion, equity and diversity of thought. They are proactive advocates of the talented women they sponsor.In this episode I am taking you through 3 of the most effective ways a Career Sponsor can help support, and fast track women through the pipeline - they are necessary catalysts to create change faster.Something Rebecca said today:"A career sponsor actively seeks out opportunities for their sponsee. Sponsors are the trailblazers of 2025, taking personal responsibility to be part of the equity solution."  (Rebecca Allen, host - Her Ambitious Career Podcast)Links:Book a call with RebeccaHead to the Illuminate websiteConnect with Rebecca on LinkedinListen to a related ep on mentoring: Learn My Bullet-Mentoring Method & Build Your Expertise Fast (ep 169)And another ep: The Bias Barrier (Part 2 of 3: 3 Major Systemic Barriers to Women's Progression ep 176)Rate, Review, & Follow our Show on Apple Podcasts:Also, if you haven't done so already, follow the podcast. We air every week and I don't want you to miss out on a single broadcast. Follow now! About Rebecca:Rebecca Allen is a Career & Leadership Coach for corporate women, aspiring to senior levels of leadership. Over the last decade, Rebecca has helped women realise their potential at companies including Woolworths, ANZ, J.P. Morgan, PwC, Coca-Cola Amatil, Ministry of Defence, Frontier Sensing and Abbvie Medical Research through her Roadmap to Senior Leadership coaching programs. Connect with Rebecca

Send a text to Melissa and she'll answer it on the next episode. The gut is far more than just a food processor—it's intimately connected to our emotional well-being, nervous system function, and overall health. In this revealing conversation, Melissa and Bri unpack the complex relationship between our minds and digestive systems, offering insights that conventional medicine often overlooks.The hosts dive deep into the world of Irritable Bowel Syndrome (IBS) and leaky gut syndrome. What makes this episode particularly valuable is the exploration of how our nervous system directly influences digestive function.  The hosts explain how oversensitive nerve endings in the digestive tract can transform normal digestive processes into painful experiences, and why childhood emotional trauma often manifests as adult gut problems. The homeopathic approach shines here as Melissa and Bri detail specific remedies that address both physical and emotional aspects of digestive disorders. Listeners will discover targeted solutions that address root causes rather than just symptoms. Whether you've struggled with digestive issues for years or simply want to understand the fascinating gut-brain connection better, this episode offers compassionate insight and practical tools to support your journey toward true gut health. Your body is communicating—are you ready to listen?Content credit: Information adapted from The Mayo Clinic:  Irritable Bowel Syndrome  Information adapted from Dr Josh Axe Leaky Gut, How to Improve Gut Health Naturally,  Most Common IBS Symptoms and What You Can Do About Them,  Do I have SIBO Symptoms? Here is ALL You Need To Know! , Natural Treatment Plan for Celiac Disease Symptoms, Colon Cancer Symptoms and The Prevention Diet,  4 Steps to Overcome Chronic Fatigue Syndrome Information adapted from The National Library of Medicine: Leaky Gut as a Danger Signal for Autoimmune , The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability, Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease, Leaky gut: mechanisms, measurement and clinical implications in humans, Leaky Gut and Autoimmunity: An Intricate Balance in Individuals Health and Diseased State Information adapted from Science Direct:  Potential mechanisms for the emerging link between obesity and increased intestinal permeabilityYou may also gain Access to my Fullscript dispensary and save 30% by going to: https://us.fullscript.com/welcome/mcrenshawFIND ME!

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197SummaryEmerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Discuss emerging data on GLP-1 RA therapy for CKD progression in T2DImplement guideline-based care to minimize CV risk and CKD progressionThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

We are delighted to welcome back Michael Fox (@runningfox26.2 on Instagram), an elite marathon runner who ran a seriously impressive 2:21 in the Dublin Marathon last year, achieved the runner-up spot at the Cork City Marathon a few weeks ago and was the winner of the recent Clonee 10k.In this episode, Michael shares invaluable insights into marathon training, from the importance of consistent training and optimal fueling strategies to overcoming the psychological challenges of racing. Michael delves deep into the transformation journey to becoming a top marathon runner. He also discusses the importance of having a support system, the nuances of personalised coaching, and the criticality of pacing during races. He also answers some of your Instagram questions that you sent in to us a few weeks ago.Whether you are a first-time marathoner or an experienced runner, Michael's tips on avoiding common pitfalls and maximising race day performance will inspire and guide your training for the Dublin Marathon 2025. 05:30 Welcome Back, Michael Fox07:46 Training and Progression in Marathons09:56 Getting into Running and Early Challenges11:55 Training Partners and VO2 Max Testing08:02 Get Coaching from Kevin Seaward and Training Adjustments20:44 Nutrition and Fuelling Strategies26:25 Advice for Marathon Beginners36:48 Training for Victory: Mindset and Motivation40:23 The Cork City Marathon 202548:18 The Importance of Proper Running Gear51:17 Balancing Family and Marathon Training: Your Support System53:02 Respecting the Marathon Challenge57:37 The Value of The Race Series in Training60:15 Final Tips and EncouragementYou can follow us on Instagram:@anygivenrundaypodcastAnd if you enjoyed this episode, go back to episode #188 to listen to Michael's complete journey into the world of marathons! This episode is sponsored by ULTRAPURE Laboratories and their new Essential Oil Muscle Rub Roll-On. Ask for the ULTRAPURE Laboratories Muscle Recovery range in your local Pharmacy or Health Store or visit their new online store and get 10% off until the end of July using the code 'AGR'Ultrapurelabs.ie You can now get 20% off all Perform Nutrition products, including their new Carb Gels, using the code 'AGR' at checkoutPerformNutrition.com

Dans cette édition :Hommages et réactions de la classe politique suite au décès du député LR Olivier Marleix, qui s'est suicidé à l'âge de 54 ans.Progression rapide d'un important incendie de forêt dans l'Aude, nécessitant l'intervention de 500 pompiers et le confinement de 2000 habitants.Négociations en cours entre Israël et le Hamas, sous l'égide des États-Unis, pour obtenir une trêve de 60 jours à Gaza.Accord entre les compagnies aériennes européennes sur les dimensions standard du bagage cabine autorisé gratuitement.Prévisions météorologiques avec un temps plus frais dans le nord et ensoleillé dans le sud de la France.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Mathilde er blandt verdens stærkeste kvinder, og hun har lige squattet 153 på en kropsvægt under 57 kg!Men vejen til Mathildes vilde comeback til både VM og DM i styrkeløft har været hård.Og faktisk var det da hun begyndte at gøre mere plads til livet ved siden af, at træningsglæden og fremgangen vendte tilbage.Lyt med på en lærerig snak med en inspirerende kvinde, om hvordan man forener et liv med både uddannelse, rejse og socialliv med meget seriøs træning.--Bliv medlem af Træningstimens gruppe på FB, og få svar på dine spørgsmål om træning og kost:https://www.facebook.com/groups/traeningstimenFå en uforpligtende samtale om din målsætning:https://styrkmig.dk/booking/Vil du støtte Træningstimen? Køb vores "Stærk hver dag" t-shirt:https://styrkmig.dk/vare/styrk-t-shirt/

Psychiatrist Carolyn Rodriguez studies hoarding disorder and says that all of us have attachments to our possessions. But for many, these attachments can disrupt daily life and even pose health risks. For those with loved ones who struggle with hoarding disorder, she says treatments exist, including cognitive behavioral therapy (CBT). Lately, she's been studying how virtual reality can augment CBT through virtual discarding practice and ways brain stimulation may improve symptoms. But, Rodriguez says, never underestimate the value of empathy for those in need of help, as she tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Carolyn RodriguezConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Carolyn Rodriguez, a professor of psychiatry and behavioral science at Stanford University.(00:02:47) Motivation to Study Hoarding DisorderWhy Carolyn chose to focus her research on hoarding disorder.(00:03:44) Collecting Versus HoardingDistinguishing between normal behavior and clinically significant hoarding.(00:05:47) Prevalence of Hoarding DisorderThe universality and pervasiveness of hoarding disorder.(00:07:11) The Brain Science Behind HoardingEarly neuroscience findings on attachment and discarding behavior.(00:08:47) Dopamine and Excessive AcquisitionThe connection between hoarding and potential dopamine reward pathways.(00:09:55) Risk Factors and Cognitive ChallengesPersonality traits, genetics, and processing difficulties involved in hoarding.(00:11:14) Gender Differences and Insight IssuesGender prevalence in treatment-seeking and the concept of anosognosia.(00:12:35) The “Why” Behind HoardingHow motivations and emotional attachments influence behavior.(00:13:50) Onset and Progression of DisorderTypical onset age, aging effects, and early warning signs.(00:15:05) Historical References to HoardingAccounts from ancient literature of hoarding-like behavior(00:17:16) Attachment to ObjectsThe emotional, aesthetic, and identity-based reasons people retain objects.(00:20:45) Current Treatment OptionsThe treatment landscape, including lack of medications and focus on CBT.(00:22:30) Chronic Nature of Hoarding DisorderFraming hoarding as a long-term condition with hopeful outcomes.(00:23:08) Virtual Reality for TreatmentA study on using VR to safely practice letting go of personal items.(00:25:58) Neuromodulation ResearchUsing non-invasive brain stimulation to reduce acquisition urges.(00:27:00) Advice for Individuals and FamiliesThe importance of empathy and self-care for individuals and caregivers.(00:28:47) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Luxe, impact, matières premières, environnement, crypto ... Chaque jour, une nouvelle thématique d'investissement !

MLB Network and Off The Mound Host Ryan Dempster joined OverDrive to discuss the headlines around the Blue Jays at a tie with the Yankees, Toronto's dynamic shifting to a positive direction, Aaron Judge's dominance, Clayton Kershaw reaching the 3,000-strikeout mark, his pitching matchups and more.

MLB Network and Off The Mound Host Ryan Dempster joined OverDrive to discuss the headlines around the Blue Jays at a tie with the Yankees, Toronto's dynamic shifting to a positive direction, Aaron Judge's dominance, Clayton Kershaw reaching the 3000-strikeout mark, his pitching matchups and more.

What is the relationship between obstructive sleep apnea and the development and progression of age-related macular degeneration? Dr. Drew Carey talks with Dr. Ahmed M. Alshaikhsalama and Dr. Amer F. Alsoudi on their recent Ophthalmology Retina article, “Association between Obstructive Sleep Apnea and Age-related Macular Degeneration Development and Progression.” Association between Obstructive Sleep Apnea and Age-related Macular Degeneration Development and Progression. Alshaikhsalama, Ahmed M. et al. Ophthalmology Retina , Volume 9, Issue 6, 537 – 545. Sign up for the next Ophthalmology Journal Virtual Club on August 27, 2025, at https://store.aao.org/ophthalmology-virtual-journal-club.html

René und Dome nehmen euch mit auf eine nostalgische Reise durch die Geschichte von Tony Hawk's Pro Skater – von den kultigen Originalen über THUG bis zum heiß erwarteten Remake von THPS 3 & 4. Es geht um prägende Soundtracks, legendäre Level und das Skateboarding-Feeling, das eine ganze Generation von Gamern mitgerissen hat.Auch die aktuellen Savegames der Jungs kommen nicht zu kurz. So berichten René und Dome von ihren Erlebnissen in FBC Firebreak und der neuen PvE-Mission in Space Marine 2.Außerdem erzählt Dome von seinen neuesten Erlebnissen bei The Legend of Zelda Tears of the Kingdom und Link's Awakening auf der Nintendo Switch 2.Viel Spaß beim Hören!Pixelburg Savegame auf Instagram, Threads,  YouTube und TikTokDominik Ollmann auf Instagram und ThreadsRené Deutschmann auf Instagram und Threads (00:00) - In dieser Folge... (00:00) - Chapter: Einführung in die Tony Hawk's Pro Skater Spiele (04:14) - Zelda-Fieber: Breath of the Wild und Tears of the Kingdom (09:23) - Link's Awakening und die Rückkehr zu alten Klassikern (11:28) - Bucketlist und Gaming-Erfahrungen der Woche (12:52) - FBC Firebreak: Multiplayer-Erfahrungen und Gameplay (17:22) - Missionen im Control-Universum und Gameplay-Elemente (18:19) - Die magischen Post-its und ihre Gegner (19:48) - Gegner-KI und Spielbalance (22:05) - Missionen und Herausforderungen (24:23) - Spielspaß und Progression (25:38) - Die Erwartungen an moderne Spiele (28:58) - Space Marine 2: Trygon-Jagd! (33:00) - Tony Hawk's Pro Skater Remake und Nostalgie (34:10) - Demo-Erfahrungen und Leveldesign (50:24) - Musik und Sounddesign im Spiel (54:22) - Nostalgie und persönliche Erfahrungen mit Tony Hawk (01:03:23) - Die Hauptreihe der Tony Hawk Spiele (01:07:42) - Die Magie der ersten Teile (01:18:18) - Die Underground-Reihe und ihre Innovationen (01:28:02) - Der Skatepark-Editor und seine Bedeutung (01:29:20) - Nebentitel und Spin-Offs der Reihe (01:31:09) - Die Kritik an Tony Hawk's Pro Skater HD (01:32:23) - Tony Hawk's Pro Skater 2X und seine Besonderheiten (01:35:59) - Die Rangliste der Hauptspiele (01:38:58) - Magische Momente und persönliche Erinnerungen (01:43:56) - Infos!

▶▶ Download my FREE Guide to Clear Sounding Chords - https://www.playguitaracademy.com/chordguide Tired of running through the same chord progressions over and over? In this quick lesson, I'll show you how to turn simple progressions into creative, engaging practice sessions that actually improve your playing. SHOW NOTES FOR THIS EPISODE- https://www.playguitaracademy.com/blog/how-to-practice-chord-progressions-without-getting-bored-423 PLAY GUITAR ACADEMY - Instant access to the tabs, backing tracks, and guitar pro files from all my lick videos, Monthly masterclasses, and weekly Q&A. https://www.playguitaracademy.com 1-on-1 Guitar Lessons - https://www.playguitaracademy.com/play-guitar-coaching PLAY GUITAR PODCAST - https://podcasts.apple.com/us/podcast/play-guitar-podcast/id1341900209 https://open.spotify.com/show/0MxjU2Y0L8PoYiTKmCtvpt YOUTUBE  (SUBSCRIBE)- https://www.youtube.com/@playguitaracademy FACEBOOK - https://www.facebook.com/PlayGuitarAcademy/ https://www.facebook.com/groups/playguitargroup/ INSTAGRAM - https://www.instagram.com/playguitaracademy Copyright ©2025 Play Guitar Academy.

An era of great technological change is unfolding before us which will transform every aspect of our lives sooner than you think.

The pen is mightier than the sword! This week we crack open that new book smell with a first edition copy of Vellum: the third-person literary hack-and-slash game. We navigate the maze-like stacks, pet some colorful wolf friends, and talk about how many puns is TOO many for understanding a game properly. Don't be quick to judge a book by it's steam store page! There's plenty of spells and quills and swords, but remember: A game a lone a last a loved a long the- Custom RSS Apple Podcasts Spotify YouTube Music Transcript 1:22 - game stats 2:50 - one sentence description 6:47 - Hub world complexity and literary theming commitment 12:37 - Overly complex terminology and ability descriptions 19:04 - Enemy design and literary theme implementation 25:33 - “One more run” phenomenon and replay motivation 29:17 - Positive aspects including UI and visual effects 33:00 - Inscription system and meta progression mechanics 38:26 - Vignette encounters and their effectiveness debate 42:54 - Tome selection system and special level rules 48:07 - Progression gating and attunement level complaints 55:39 - End game content and endless mode discussion 1:01:29 - Boss strategy discovery and magical lamp exploit 1:14:13 - rankings and final thoughts 1:22:08 - similar games 1:24:50 - listener correspondence: does the GROGPOD need a public discord channel? Next episode: 2025 Summer Music Fest Contact us at grogpodzone@gmail.com! https://grogpod.zone Intro music: My Little Brown Book - Duke Ellington, John Coltrane Outro music: Vellum OST - Boss Battle

In this episode of PTs Snacks podcast, host Kasey Hankins covers proximal hamstring tendinopathy, a common issue for runners and athletes. She describes the causes and symptoms, highlights the importance of proper diagnosis, and outlines a progressive loading system for treatment.00:00 Introduction to Proximal Hamstring Tendinopathy00:44 Understanding Proximal Hamstring Tendinopathy02:29 Diagnosing Proximal Hamstring Tendinopathy03:58 Key Tests and Assessments05:28 Treatment Approaches and Phases07:24 Advanced Rehabilitation Techniques08:21 Returning to Sport and Monitoring Progress09:47 Conclusion and Additional ResourcesSupport the showWhy PT Snacks Podcast?This podcast is your go-to for bite-sized, practical info designed for busy, overwhelmed Physical Therapists and students who want to build confidence in their foundational knowledge without sacrificing life's other priorities. Stay Connected! Never miss an episode—hit follow now! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. Join the email list HERE On Instagram? Find unique content at @dr.kasey.hankins! Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less!(These are affiliate links, but I only recommend Medbridge because it's genuinely valuable.) Optimize Your Patient Care with Tindeq Looking for a reliable dynamometer to enhance your clinical measurements? Tindeq ...

What's the difference between being paid for your emotional labor and giving it away for free? In this episode of the Sex Work VS miniseries, I explore how sex work reshaped my approach to relationships. From unreciprocated efforts with cis-het men to the gratitude that comes with being paid, I reflect love, and raising my standards. We'll talk about oxytocin, one-sided coaching, the myth of romantic stability—and why financial independence feels far more secure. This isn't about giving up on intimacy. It's about knowing your worth, and deciding who (or what) deserves your time.Watch on YouTube: https://youtube.com/evaohMore on Eva Oh: https://eva-oh.comHIGHLIGHTS:Here are the timestamps for the episode. On some podcast players you should be able to click the timestamp to jump to that time.(00:00) - Welcome. What is #teakink(00:21) - Sex Work VS Relationships(01:05) - The 'Natural' Progression, Dating to Relationship?(02:15) - What I Would Need from a Relationship(03:40) - The Societal Expectation of Having a Relationship(07:10) - Being Taken for Granted(09:10) - The Advantage of Paid VS Unpaid Emotional and Sexual Labour(10:30) - One-sided Efforts when Engaging with Cis-het Men(13:25) - Improving My Standards, Does it Help or Hinder(15:40) - Getting Paid for the Usual Coaching of Men(16:40) - The Exchange of Money Encourages Gratitude(20:40) - Honing the Art of Relating and the Benefits of Getting Paid for It(23:15) - Relationship Stability is not a Given, your Financial Independence can be(24:50) - Do I Want to Spend My Life on Unworthy Pursuits and People?(25:50) - Falling in Love as a Skill Learned through Sex Work(26:55) - Friendships with Sex Workers as the Gold Standard(27:45) - The Need for Reciprocation(28:55) - What Cis-het Men Could Offer if Not My Gold Standard, Money and Connections

In this episode of From the Pasture with Hired Hand, we talk with Kris Johnson from I M Bar Longhorns located in Big Horn, Wyoming. I M Bar Ranch has been in his family for close to 100 years and raising Texas Longhorns since 1995. Their main focus is producing complete cattle with a pile of horn while still being able to go out and compete in any show across the nation. Kris is a man who wears many cowboy hats. He is not only a rancher, he is the Region 16 Director for the TLBAA, the Wyoming Longhorn Association President, a committee member for the World Show for the TLBAA, & the Superintendent for the Nile Stock Show in Billings, Montana: Longhorn Division.  Listen today to learn about Kris and I M Bar Longhorn Ranch. I M Bar Longhorns: http://www.imbarlonghorns.comSend us a textFrom the Pasture with Hired Hand:Hired Hand Websites (@hiredhandwebsites): https://hiredhandsoftware.comHired Hand Live (@hiredhandlive): https://hiredhandlive.comInstagram: https://www.instagram.com/hiredhandwebsites/Facebook: https://www.facebook.com/HiredHandSoftwareTikTok: https://www.tiktok.com/@hiredhandwebsitesNewsletter: https://www.hiredhandsoftware.com/resources/stay-informed

Good Temps is back! This is a recurring podcast focused on the latest things happening in climbing and what it means for our sport from industry veterans: Carlo Traversi, Will Anglin, Austin Hoyt, and Joshua Horsley.Today's episode covers:Brooke Rabatou's FFA of Excalibur (15c)Adam Ondra flashing Lexicon (E11)Mount Doom (V17) and the importance of aesthetics, which leads to a discussion about how our sport actually progressesMellow Rock GamesControversy around Sung Su's sending Burden of Dreams (V17)Support the showSupport us on Patreon: HEREVisit our podcast page: HERESign-up with one of our coaches: HEREFollow us on Instagram: HERE

David Olsen, Director of State Affairs for the Alzheimer’s Association, joins Lisa Dent to talk about Illinois becoming the first state to require insurance to provide coverage for Alzheimer's treatments that slow the progression of Alzheimer’s.

If a person doesn't want you life isn't over! Stop allowing negative thoughts to cause you to act out! If you give power to negative thoughts they can consume and control you! Love yourself enough to know when you need to move on! Love yourself enough to not want someone who doesn't want you! Love yourself enough to be the best you can be! Many people never get to the level of maturity they deserve, because they're in their own way and their worst enemy is their mindset! You can't grow or become the best you can be by remaining the same!Become a supporter of this podcast: https://www.spreaker.com/podcast/relationships-and-relatable-life-chronicles--4126439/support.

Pivot Family! We are out here in Salt Lake City checking out a whole new world for us as we are on site for the 2025 X Games! As the X Games get underway, The Pivot Podcast sits down with two of the most explosive names in action sports — Ryan Williams, the BMX innovator pushing the limits of what's possible, and Dashawn Jordan, the street skater known for his power, precision, and style. Two completely different approaches to each's sport, but unified by the same goal- compete to win. Ryan, Channing and Fred get introduced to the extreme side of action sports, the high risk-high reward mentality and the laser focus needed to lock in on the one opportunity that measures success or failure. We talk mindset, motivation, and mayhem — from landing never-been-done tricks to staying locked in under pressure. Ryan and Dashawn open up about their journeys, what it takes to stay at the top, and what fans can expect at this year's X Games. Whether it's the mega ramp or the street course, these athletes are ready to redefine progression. Don't miss this raw and real conversation with two athletes redefining their sports and giving us a glimpse of what it takes to compete at the highest level. Comment and let us know what you think! Learn more about your ad choices. Visit megaphone.fm/adchoices

Tous les jours dans la matinale d'Europe 1, Olivier de Lagarde scrute et analyse la presse du jour. Aujourd'hui, le palmarès 2025 des escrocs, la dette de la France s'aggrave de 40 milliards en trois mois, la progression des incivilités et un reportage à Montargis deux ans après les émeutes liées à la mort de Nahel. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In Colorado, Barry Morphew is arrested for the second time for the murder of his wife, Suzanne, who disappearedon Mother's Day in2020. In Bowling Green, Kentucky, two men go on trial for the murder of mom Crystal Rogers. Updates on Monica Sementilli and former MLB pitcher Dan Serafini. Plus, we've all seen age-progressedimagesofmissingchildren — can they actually help?See more of Dateline's reporting on missing persons cases in which age-progressed images are featuredhere:https://www.nbcnews.com/age-progressionsFind out more about the cases covered each week here:www.datelinetruecrimeweekly.com

Much of the scientific process involves searching. But rather than continue to rely on the luck of discovery, Google DeepMind has engineered a more efficient AI agent that mines complex spaces to facilitate scientific breakthroughs. Sarah Guo speaks with Pushmeet Kohli, VP of Science and Strategic Initiatives, and research scientist Matej Balog at Google DeepMind about AlphaEvolve, an autonomous coding agent they developed that finds new algorithms through evolutionary search. Pushmeet and Matej talk about how AlphaEvolve tackles the problem of matrix multiplication efficiency, scaling and iteration in problem solving, and whether or not this means we are at self-improving AI. Together, they also explore the implications AlphaEvolve has to other sciences beyond mathematics and computer science. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @pushmeet | @matejbalog Chapters: 00:00 Pushmeet Kohli and Matej Balog Introduction 0:48 Origin of AlphaEvolve 02:31 AlphaEvolve's Progression from AlphaGo and AlphaTensor 08:02 The Open Problem of Matrix Multiplication Efficiency 11:18 How AlphaEvolve Evolves Code 14:43 Scaling and Predicting Iterations 16:52 Implications for Coding Agents 19:42 Overcoming Limits of Automated Evaluators 25:21 Are We At Self-Improving AI? 28:10 Effects on Scientific Discovery and Mathematics 31:50 Role of Human Scientists with AlphaEvolve 38:30 Making AlphaEvolve Broadly Accessible 40:18 Applying AlphaEvolve Within Google 41:39 Conclusion

In Colorado, Barry Morphew is arrested for the second time for the murder of his wife, Suzanne, who disappeared on Mother's Day in 2020. In Bowling Green, Kentucky, two men go on trial for the murder of mom Crystal Rogers. Updates on Monica Sementilli and former MLB pitcher Dan Serafini. Plus, we've all seen age-progressed images of missing children — can they actually help?See more of Dateline's reporting on missing persons cases in which age-progressed images are featured here: https://www.nbcnews.com/age-progressions Find out more about the cases covered each week here: www.datelinetruecrimeweekly.com

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

This week on The Road to the Cross, Tim and Steve dive into one of the most influential ideas in Western Christianity: original sin. How did a fifth-century theory by Augustine come to dominate our understanding of salvation, the cross, and even our identity?Tracing the theology from Eden to empire, they uncover a progression that reshaped how many Christians understand God's character—introducing fear, shame, and legalism into what was meant to be good news.

Toronto Blue Jays Infielder and Outfielder Addison Barger joined OverDrive to discuss his impressive season with the Blue Jays, the experience throughout the start at bat, playing the guitar, the atmosphere of the team, his approach with power, his strength towards the top of the lineup and more.

Hey everyone! Alex and KJ dive into the Packers-Bears rivalry in today's show after Caleb Williams got it going over the weekend. The brothers also touch on the roster, division competition, and more. Welcome Back to the IKE Packers Podcast!Help the show by telling another Packers fan! Other ways to contribute are by leaving a 5-star review on Apple Podcasts and subscribing wherever you get your podcasts.@IKE_Packers on X

In this episode of the Transform Sales Podcast: Sales Software Review Series, Dave Menjura

TSN Soccer Reporter Matthew Scianitti joined OverDrive to discuss the headlines around CONCACAF's investigation in Jesse Marsch for his incidents at the Gold Cup, his ferocious character on the sideline, Canada Soccer's team foundation, the relationship with Alphonso Davies, the future of the organization and more.

When High Conflict Takes You By SurpriseLife can change dramatically when you unexpectedly encounter a person who demonstrates high conflict behavior. Bill Eddy and Megan Hunter from the High Conflict Institute in Scottsdale, Arizona, explore the unsettling experience of being blindsided by high conflict situations—whether in a new job, relationship, or family dynamic.Understanding the Impact of Unexpected High ConflictWhen high conflict behavior emerges unexpectedly, it often creates a destabilizing ripple effect. The initial confusion and self-doubt can leave anyone questioning their capabilities and judgment. This episode examines how these situations develop, from the early stages of confusion through the progression of mounting tension and isolation.Recognizing High Conflict PatternsThe most challenging aspect of surprise high conflict situations is their ability to create self-doubt in even the most confident individuals. What begins as an attempt to improve communication or performance often escalates into a pattern of increasing criticism and isolation. Understanding these patterns helps identify when you're dealing with high conflict behavior rather than typical workplace or relationship challenges.Questions We Answer in This EpisodeHow do you recognize when self-doubt stems from high conflict behavior?What makes group high conflict situations especially challenging?Why do attempts to "try harder" often backfire with high conflict people?How can you protect yourself from high conflict surprises?Key TakeawaysRemember "It's not about me" when facing unexpected criticism90% of people don't engage in high conflict behaviorPhysical distance can help manage high conflict situationsTrust your experience with non-high conflict relationshipsSetting clear limits with consequences can be effectiveHigh conflict surprises can happen to anyone, anywhere. This episode provides practical insights for recognizing, understanding, and managing these challenging situations while maintaining your confidence and perspective.Additional ResourcesExpert PublicationsIt's All Your Fault at Work! Dealing with Narcissists and Other High-Conflict People - Managing High Conflict Workplace Dynamics5 Types of People Who Can Ruin Your Life - Understanding High Conflict BehaviorProfessional DevelopmentNew Ways for Couples & Families: Online relationship strengthening courseConflictInfluencer.com: Advanced conflict management training (Coming Soon)Connect With UsVisit High Conflict Institute: highconflictinstitute.comSubmit questions for Bill and MeganBrowse our complete collection of books and resources in our online store—available in print and e-book formatsFind these show notes and all past episode notes on our websiteImportant NoticeOur discussions focus on behavioral patterns rather than diagnoses. For specific legal or therapeutic guidance, please consult qualified professionals in your area. (00:00) - Welcome to It's All Your Fault (01:32) - High Conflict Surprises (02:37) - Updates (03:32) - Bill's Example (09:07) - What Happens In Our Minds (11:03) - Progression and Impact (13:02) - CARS Method (20:23) - Recentering Yourself (23:59) - New on the Job (26:08) - High Conflict Traps (27:19) - Target of Blame (29:00) - Larger Groups (31:42) - Wrap Up (32:44) - Reminders Learn more about our New Ways for Work Coaching sessions. Get started today!

Damien and Ali get In The Conversation about new holidays, Father's Day reflection, and having something to do. Twitter.com/dlemoncomedy // Twitter.com/mrmuhammad Keep up with the conversation on Instagram www.instagram.com/intheconversation

In this episode, Camila returns to Grief Out Loud six years after her first appearance to share how grief continues to evolve. What began with the sudden loss of her mother at age 21 has now expanded to include the ongoing grief of caregiving for her father, who is living with dementia and Alzheimer's disease.  Camila discusses the unique challenges of long-distance caregiving, the differences between sudden loss and gradual decline, and how these two types of grief intersect in her life. She also discusses navigating major life milestones—including getting married during the pandemic—without her mother's presence.  We Discuss: The difference between sudden loss and the "slow grief" of watching a parent decline  How grief has shifted in the 15+ years since her mother's unexpected death Losing her father as the co-archivist of her mother's life and their family history Managing long-distance caregiving The failures of the elder care system in the U.S. The role of chosen family and support Wedding planning and the question of how to honor her mother's memory  The complexity of being a queer person in traditionally heteronormative grief support spaces  Feeling like she no longer has parents, even though her father is still alive  The therapeutic value of pets  Finding moments of connection and joy with her father despite his condition  Using poetry as a processing tool for grief  About the Guest:  Camila is a poet who has published three books of poetry:  The Progression of Grief (about losing her mother)  New Waters (about falling in love and healthy relationships)  The Longevity of Grief (about caring for her father and how different types of grief intersect) This episode is the third in our 2025 three-part series highlighting the voices of communities who have historically been underrepresented in the grief world. The series is part of an ongoing collaboration between Dougy Center and The New York Life Foundation. We are deeply grateful for New York Life Foundation's tireless support and advocacy for children and teens who are grieving. Grief Out Loud is a production of Dougy Center, the National Grief Center for Children and Families in Portland, Oregon.

Ever go into the gym, lift weights, and wonder if you are actually making progress? You are not alone. One of the most common questions I get is how to know when it is the right time to increase weight, add reps, or push harder in a workout. The truth is, most people are just guessing, which leads to randomness and stalled results. In this episode, I break down a simple strategy we use with our clients at Fit for Life Academy called dynamic double progression. It takes the guesswork out of training by giving you a clear and flexible system to track your progress and know exactly when to make adjustments. We cover why progressive overload is essential, what it really means to do more over time, and how to apply this system to your own workouts to build strength and muscle consistently. If you have ever felt stuck or unsure whether you are training effectively, this episode will give you the clarity and structure you need to move forward with confidence. Tune in and start making every workout count. Download my FREE Nutrition for Fat Loss eBook:  https://fit4lifeacademy.health/blueprint Apply to work with us at Fit4Life Academy: https://fit4lifeacademy.health/vsl-page I can't wait to hear your thoughts on this episode. Stay healthy and inspired.

The Denver Broncos' offseason program is over.Did Bo Nix perform above or below expectations? Which receivers were his top targets? Was Que Robinson or RJ Harvey the Denver Broncos' top rookie? Who needs to step up in training camp?The guys break down all of the biggest lessons from the Denver Broncos' OTAs and minicamp.In honor of Friday the 13th, the guys draft the scariest Denver Broncos in team history.On the DNVR Broncos Podcast, Zac Stevens, Ryan Koenigsberg and Henry Chisholm are coming to you LIVE from the DNVR Bar to break down all of the latest news in Broncos Country. Start: 0:00Biggest takeaway from the offseason so far: 5:15Bo Nix's improvement: 13:11Defense improvement: 19:56Offseason takeaways from rookies: 33:20Friday draft: 52:00 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events ALL THINGS DNVR: https://linktr.ee/dnvrsports BALL-KNOWER BONUS/Merch: https://promotion.allcitynetwork.com/promotions/store.allcitynetwork/7d48d294-4260-4bac-aca1-9a18eef8ca78 SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Toyota: Visit Your Front Range Toyota Stores at a location near you - Toyota is the official vehicle of DNVR. Toyota - Let's Go Places! Toyota Drive to the Playoffs: https://kse.jotform.com/250624177000950?camefrom=CFC_KSE_xJZqkfEGc0GvJpltfPs0pA&utm_[…]um=xJZqkfEGc0GvJpltfPs0pA&utm_campaign=xJZqkfEGc0GvJpltfPs0pA First Bank: So, if you're ready for better banking and the chance to earn a little extra, head to efirstbank.com/bonus. Certain restrictions and requirements apply. Member FDIC. Hall of Fame App: Get a 7-Day Free Trial + 50% Off your first month with code DNVR. Just download the HOF app on iOS and Android or visit www.hofbets.com, enter code DNVR, and you're all set. #ad Raising Cane's Rooftop Fridays: https://thednvr.com/event/friday-rooftop-club-at-coors-field-presented-by-raising-canes/   Monarch Money: Use Monarch Money to get control of your overall finances with 50% off your first year at https://www.monarchmoney.com/dnvr  bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLERUCHealth: Learn more about Living Like There's A Tomorrow at https://www.uchealth.org/tomorrow/?utm_source=DNVR&utm_medium=Audio&utm_campaign=Brand_LLTIAT_Null_JFMFY25_AW_Null Empire Today: Schedule a free in-home estimate today! All listeners can receive a $350 OFF discount when they use the promo code DNVR. Restrictions apply. See https://empiretoday.com/dnvr for details Coors Light:  Delivery on Instacart at https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Gametime: Download the app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Shady Rays: Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. Rugged Road: Gear up for your next adventure with Rugged Road Coolers - Your ultimate outdoor companion! Head to http://ruggedroadoutdoors.pxf.io/ALLCITY and use code DNVR for 10% off!   Hello Fresh - Get 10 FREE meals at https://hellofresh.com/freebroncos. Applied across 7 boxes, new subscribers only, varies by plan. When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.